Nevertheless, pembrolizumab, nivolumab, and atezolizumab have all displayed similar superior efficacy over docetaxel in previously treated NSCLC patients (9,12–15), and meta-analysis has found no statistically significant observable difference between PD-1 inhibitors and PD-L1 inhibitors (16). This evidence concerns the gene CD274 and non-small cell lung carcinoma.